Zymeworks Inc. Common Shares (ZYME) Social Stream



Zymeworks Inc. Common Shares (ZYME): $5.99

0.17 (+2.92%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ZYME to Watchlist
Sign Up

Industry: Biotech


Ranked

of 395

in industry

Zymeworks Inc (ZYME) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering ZYME.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-04 8 $74 $28 $48.875 $6.66 633.86%
2021-11-10 8 $74 $27 $48.75 $6.66 631.98%
2021-11-17 9 $74 $27 $47.875 $6.66 618.84%
2021-12-10 9 $74 $27 $47.875 $6.66 618.84%
2021-12-14 9 $74 $27 $45.375 $6.66 581.31%
2022-01-24 9 $51 $27 $40.857 $6.66 513.47%
2022-02-01 8 $51 $27 $37.571 $6.66 464.13%
2022-02-24 8 $51 $18 $34.714 $6.66 421.23%
2022-03-15 9 $44 $15 $28.875 $6.66 333.56%

The Trend in the Analyst Price Target


ZYME's average price target has moved down $20 over the prior 131 days.

ZYME reports an average of 262.95% for its upside potential over the past 131 days.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-11-17 9 74 27 47.875 19.58 144.51%
2021-12-10 9 74 27 47.875 16.07 197.92%
2021-12-14 9 74 27 45.375 15.91 185.2%
2022-01-24 8 51 27 40.857 10.00 308.57%
2022-02-01 8 51 27 36.000 8.41 328.06%

ZYME Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.78 5 1 3 0 0 9

The Trend in the Broker Recommendations


ZYME's average broker recommendation rating improved by 0.22 over the prior 120 days.

The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.

  • Zymeworks Inc's upside potential (average analyst target price relative to current price) is higher than 1056.21% of all US stocks.
  • To contextualize these metrics, consider that out of all US stocks, Zymeworks Inc's variance in analysts' estimates is lower than -843.49% of them.
  • In the context of Pharmaceutical Products stocks, Zymeworks Inc's number of analysts covering the stock is greater than 789.13% of them.
  • To contextualize these metrics, consider that out of Pharmaceutical Products stocks, Zymeworks Inc's average analyst price target is greater than 671.69% of them.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to Zymeworks Inc are ZNTL, YMAB, and XNCR.

Make investment decisions regarding ZYME using the data that counts. Try POWR Ratings for free.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.9751 seconds.